Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2355)	10/16/1997 9:32:00 AM
From: Henry Niman	of 6136

Peter, The time for resistance should be directly related to the viral load, which is a strong arguement for early treatment, even with PI niave patients. The recent data shows just how quickly such mutations can produce detectable virus when patients have been previously treated (even if the treatment regime doesn't include a PI) and/or their viral load is high. However, current assays only show the tip of the iceburg. Popular assays have a detection limit of 500 copies / ml. Thus, undectable is far from eliminated and this will become clearer when a more sensitive assay of 50 copies / ml is more widely used (and of course "undectable" in the more sensitive assay also does not translate into eliminated).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next